Strictly necessary cookies help to make the website usable by enabling basic functions such as site navigation and access to secure sections of the website. The website cannot function properly without these cookies.
Preference cookies allow a website to remember information that changes how a website behaves or looks. For example, your preferred language or the region you are in.
Statistical cookies help website owners to understand how visitors use the website. They collect and communicate information anonymously.
Marketing cookies are used to track visitors to the website. The intention is to display advertising that is relevant and interesting to the individual user and thus more valuable to publishers and third-party advertisers.
This website uses cookies
We use cookies to personalise content and ads, provide social media features and analyse our traffic. We share information about how you use our website with our social media, advertising and analytics partners. Partners may combine this information with other information you provide to them or that they obtain as a result of your use of their services.
ApoA1 (Apolipoprotein A1) is synthesized in the liver and small intestine, and is the major protein component of high density lipoprotein (HDL) in the plasma. ApoA1 has a unique ability to capture and solubilize free cholesterol, and promotes cholesterol efflux from tissues to the liver for excretion. The process, called reverse cholesterol transport, is thought to inhibit atherogenesis.
Description ApoA1 (Apolipoprotein A1) is synthesized in the liver and small intestine, and is the major protein component of high density lipoprotein (HDL) in the plasma. ApoA1 has a unique ability to capture and solubilize free cholesterol, and promotes cholesterol efflux from tissues to the liver for excretion. The process, called reverse cholesterol transport, is thought to inhibit atherogenesis. The recombinant human ApoA1 consists of 244 amino acids and predicts a molecular mass of 28.2 KD.
Applications
miRNA in vivo delivery
HDL Assembly
Evaluation of risk for atherosclerotic cardiovascular disease
Source: Human
Expression System:E. coli
Tag: N-terminal His-tag
Purity: >95% as determined by SDS-PAGE
Endotoxin Level: Less than 0.1EU/ug by LAL method
Recommended Storage Condition: -20°C
Expiration date: 12 months
APO-100 or APOH-100
New
Comments (0)
No customer reviews for the moment.
Your review appreciation cannot be sent
Report comment
Are you sure that you want to report this comment?
Report sent
Your report has been submitted and will be considered by a moderator.
Your report cannot be sent
Write your review
Review sent
Your comment has been submitted and will be available once approved by a moderator.
Biotin-protein ligase (EC 6.3.4.15) activates biotin to form biotinyl 5' adenylate and transfers the biotin to biotin-accepting proteins. It also functions as a biotin operon repressor.
Ciliary neurotrophic factor (CNTF) s a polypeptide initially purified from chick embryo ocular tissue and identified as a trophic factor for embryonic chick ciliary parasympathetic neurons in culture.
Human Nicotinamide Phosphoribosyltransferase (NAMPT) catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, one step in the biosynthesis of nicotinamide adenine dinucleotide.
Human Brain-Derived Neurotrophic Factor (BDNF) is a member of the Nerve growth factor family. BDNF is induced by cortical neurons, and is necessary for survival of striatal neurons in the brain. During development, BDNF promotes the survival and differentiation of selected neuronal populations of the peripheral and central nervous systems.
Streptavidin is a non-glycosylated, 52.8 kDa, tetrameric bacterial protein isolated from Streptomyces avidinii with a very high affinity for biotin. Streptavidin-biotin bond is the strongest known non-covalent interaction with Kd ~10-15 M. Because streptavidin lacks any carbohydrate modification and has a near-neutral pI, it has the advantage of much lower nonspecific binding than avidin.
ApoA1 (Apolipoprotein A1) is synthesized in the liver and small intestine, and is the major protein component of high density lipoprotein (HDL) in the plasma. ApoA1 has a unique ability to capture and solubilize free cholesterol, and promotes cholesterol efflux from tissues to the liver for excretion. The process, called reverse cholesterol transport, is thought to inhibit atherogenesis.